Merck KGaA, Darmstadt, Germany: Neoplasms trials

The registry lists 28 Neoplasms studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 1 are open to participants now and 18 have results posted.

Phase 1 23Phase 2 2Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Met Non Small Cell Cancer Registry (MOMENT)RecruitingNCT05376891
• Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)CompletedNCT05246111Phase 1Results posted
• Bintrafusp Alfa Program Rollover StudyCompletedNCT05061823Phase 3Results posted
• First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)CompletedNCT04882917Phase 1Results posted
• Study of Avelumab-M3814 CombinationsCompletedNCT03724890Phase 1Results posted
• M3541 in Combination With Radiotherapy in Solid TumorsTerminatedNCT03225105Phase 1Results posted
• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Phase 2Results posted
• First in Human Study of M4344 in Participants With Advanced Solid TumorsCompletedNCT02278250Phase 1Results posted
• Relative Bioavailability of Pimasertib in Cancer PatientsCompletedNCT01992874Phase 1Results posted
• Japanese Phase 1 Trial of Sym004 in Solid TumorsCompletedNCT01955473Phase 1Results posted
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)CompletedNCT01943461Phase 1Results posted
• A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid TumorsCompletedNCT01832506Phase 1Results posted
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)CompletedNCT01772004Phase 1Results posted
• MSC2015103B in Solid TumorsTerminatedNCT01453387Phase 1Results posted
• Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT01390818Phase 1Results posted
• A Study of EMD525797 in Solid Tumor Patients in JapanCompletedNCT01327313Phase 1Results posted
• First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid TumorsCompletedNCT01014936Phase 1Results posted
• Trial of MSC1936369B in Subjects With Solid TumorsCompletedNCT00982865Phase 1Results posted
• Trial of Pimasertib in Hematological MalignanciesTerminatedNCT00957580Phase 2Results posted
• Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1
• M6620 First in Human StudyCompletedNCT02157792Phase 1
• First-in-Human Dose Escalation Trial in Subjects With Advanced MalignanciesCompletedNCT01971515Phase 1
• Cilengitide Imaging Trial in GlioblastomaTerminatedNCT01558687Phase 1
• An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal CancerTerminatedNCT01134666
• First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid TumorsTerminatedNCT01110083Phase 1
• A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological MalignanciesTerminatedNCT01080664Phase 1
• EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid TumorsCompletedNCT01012102Phase 1
• AS703569 Phase I in Patients With Solid TumoursCompletedNCT00391521Phase 1